About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
CagriSema
- Company
- Novo Nordisk
- Mechanism
- dual GLP-1/amylin
- Route
- Injectable
- Recruiting trials
- 10 recruiting
Next milestone: FDA decision
10 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026
Find a Clinical Trial Near Me
See recruiting studies for CagriSema and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT07010432
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
Not yet reported Novo Nordisk A/S 144 participants Est. completion 2028-05-03 1 site MixedOther conditions: ObesityView official trial listing → -
Recruiting NCT NCT07253285
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Not yet reported Novo Nordisk A/S 460 participants Est. completion 2033-09-20 121 sites MixedOther conditions: Overweight, ObesityView official trial listing → -
Recruiting NCT NCT07282613
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Not yet reported Novo Nordisk A/S 80 participants Est. completion 2030-03-30 58 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Recruiting NCT NCT07411560
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
Not yet reported Novo Nordisk A/S 100 participants Est. completion 2027-01-26 1 site Stand-aloneOther conditions: Overweight, ObeseView official trial listing → -
Recruiting NCT NCT07527195
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Not yet reported Novo Nordisk A/S 100 participants Est. completion 2028-06-09 1 site MixedOther conditions: ObesityView official trial listing → -
Recruiting NCT NCT07557953
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
Not yet reported Novo Nordisk A/S 120 participants Est. completion 2027-04-13 1 site Stand-aloneOther conditions: Overweight, ObesityView official trial listing → -
Recruiting NCT NCT07564414
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
Not yet reported Novo Nordisk A/S 2500 participants Est. completion 2028-04-19 303 sites Stand-aloneType 2 diabetes Other conditions: ObesityView official trial listing → -
Recruiting NCT NCT07597018
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
Not yet reported Novo Nordisk A/S 234 participants Est. completion 2027-06-01 1 site MixedOther conditions: Obesity, OverweightView official trial listing → -
Recruiting NCT NCT07607587
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
Not yet reported Novo Nordisk A/S 114 participants Est. completion 2027-11-19 11 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Recruiting NCT NCT07745504
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Not yet reported Novo Nordisk A/S 285 participants Est. completion 2027-07-06 36 sites Added to GLP-1Other conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT04940078
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
Not yet reported Novo Nordisk A/S 40 participants Est. completion 2022-02-16 2 sites Added to GLP-1Other conditions: Obesity & OverweightView official trial listing → -
Completed NCT NCT04982575
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Not yet reported Novo Nordisk A/S 92 participants Est. completion 2022-07-07 23 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT05394519
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Not yet reported Novo Nordisk A/S 1200 participants Est. completion 2025-02-03 179 sites Added to GLP-1Type 2 diabetes Other conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT05564104
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
Not yet reported Novo Nordisk A/S 32 participants Est. completion 2024-12-19 4 sites Stand-aloneOther conditions: Hepatic Impairment, Healthy VolunteersView official trial listing → -
Active, not recruiting NCT NCT05567796
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Not yet reported Novo Nordisk A/S 3400 participants Est. completion 2026-10-19 256 sites Added to GLP-1Other conditions: ObesityView official trial listing → -
Active, not recruiting NCT NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Not yet reported Novo Nordisk A/S 7101 participants Est. completion 2027-10-14 633 sites Added to GLP-1Cardiovascular diseaseView official trial listing → -
Completed NCT NCT05804162
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
Not yet reported Novo Nordisk A/S 107 participants Est. completion 2023-09-18 1 site Stand-aloneOther conditions: ObesityView official trial listing → -
Completed NCT NCT05813925
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Not yet reported Novo Nordisk A/S 331 participants Est. completion 2025-03-07 28 sites Added to GLP-1Other conditions: Obesity or OverweightView official trial listing → -
Completed NCT NCT05996848
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Not yet reported Novo Nordisk A/S 300 participants Est. completion 2025-02-22 37 sites Added to GLP-1Other conditions: Obesity or OverweightView official trial listing → -
Completed NCT NCT06065540
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Not yet reported Novo Nordisk A/S 2734 participants Est. completion 2026-01-06 405 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT06131372
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Not yet reported Novo Nordisk A/S 626 participants Est. completion 2025-11-06 128 sites MixedChronic kidney diseaseType 2 diabetes Other conditions: ObesityView official trial listing → -
Completed NCT NCT06131437
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Not yet reported Novo Nordisk A/S 809 participants Est. completion 2026-01-09 46 sites Added to GLP-1Other conditions: ObesityView official trial listing → -
Completed NCT NCT06207877
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
Not yet reported Novo Nordisk A/S 62 participants Est. completion 2024-11-22 1 site Added to GLP-1Other conditions: ObesityView official trial listing → -
Completed NCT NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Not yet reported Novo Nordisk A/S 1024 participants Est. completion 2026-04-06 197 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT06267092
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Not yet reported Novo Nordisk A/S 164 participants Est. completion 2025-12-08 1 site Added to GLP-1Other conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT06289504
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Not yet reported Novo Nordisk A/S 34 participants Est. completion 2024-11-15 1 site Added to GLP-1Other conditions: ObesityView official trial listing → -
Completed NCT NCT06323161
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Not yet reported Novo Nordisk A/S 274 participants Est. completion 2025-10-23 61 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT06323174
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Not yet reported Novo Nordisk A/S 189 participants Est. completion 2025-12-22 50 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Not yet reported Novo Nordisk A/S 300 participants Est. completion 2026-04-22 25 sites Added to GLP-1Other conditions: ObesityView official trial listing → -
Completed NCT NCT06403761
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Not yet reported Novo Nordisk A/S 158 participants Est. completion 2026-02-02 1 site MixedType 2 diabetesView official trial listing → -
Completed NCT NCT06409130
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Not yet reported Novo Nordisk A/S 270 participants Est. completion 2026-01-12 102 sites Added to GLP-1Other conditions: Alcohol-related Liver DiseaseView official trial listing → -
Completed NCT NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Not yet reported Novo Nordisk A/S 1023 participants Est. completion 2026-07-09 163 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT06716307
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity
Not yet reported Novo Nordisk A/S 18 participants Est. completion 2025-03-28 1 site Added to GLP-1Other conditions: ObesityView official trial listing → -
Completed NCT NCT06719011
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Not yet reported Novo Nordisk A/S 178 participants Est. completion 2026-07-20 2 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Active, not recruiting NCT NCT06780449
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Not yet reported Novo Nordisk A/S 400 participants Est. completion 2028-10-31 36 sites Added to GLP-1Other conditions: ObesityView official trial listing → -
Completed NCT NCT06797869
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Not yet reported Novo Nordisk A/S 142 participants Est. completion 2026-08-05 55 sites Added to GLP-1Type 2 diabetes Other conditions: Diabetic Peripheral NeuropathyView official trial listing → -
Active, not recruiting NCT NCT07011667
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Not yet reported Novo Nordisk A/S 609 participants Est. completion 2028-10-17 46 sites Added to GLP-1Other conditions: ObesityView official trial listing → -
Active, not recruiting NCT NCT07184086
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
Not yet reported Novo Nordisk A/S 80 participants Est. completion 2028-02-09 2 sites Added to GLP-1Other conditions: ObesityView official trial listing → -
Active, not recruiting NCT NCT07220642
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Not yet reported Novo Nordisk A/S 300 participants Est. completion 2027-06-29 40 sites Stand-aloneOther conditions: Obesity, OverweightView official trial listing → -
Active, not recruiting NCT NCT07220759
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Not yet reported Novo Nordisk A/S 330 participants Est. completion 2027-06-30 67 sites Stand-aloneType 2 diabetes Other conditions: Overweight, ObesityView official trial listing → -
Withdrawn NCT NCT07357740
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Not yet reported Novo Nordisk A/S Est. completion 2027-10-13 61 sites Stand-aloneType 2 diabetesView official trial listing → -
Withdrawn NCT NCT07357766
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Not yet reported Novo Nordisk A/S Est. completion 2028-01-17 116 sites Stand-aloneOther conditions: Overweight, ObesityView official trial listing → -
Completed NCT NCT07605052
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
Not yet reported Novo Nordisk A/S 50 participants Est. completion 2026-08-19 1 site Stand-aloneOther conditions: Overweight, ObesityView official trial listing →
Efficacy history
Absolute change weight loss · 68 weeks
Adults with obesity or overweight, without type 2 diabetes
Trial: REDEFINE 1 (Phase 3)
Source →Results from different trials are not directly comparable — populations, timepoints, and measurement methods differ between studies.
Safety
Not yet reported.
Sources
Also known as: CagriSema, cagrilintide / semaglutide, cagrilintide, CagriSema (Cagrilintide B + semaglutide I), CagriSema (Cagrilintide B and Semaglutide I)
Related On The Pen coverage
The Weekly Dose & livestreams
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.